Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial

被引：18
|
作者：
Frenel, J-S. [1 ,2 ]
Kim, J-W. [3 ]
Berton-Rigaud, D. [1 ,2 ]
Asher, R. [4 ]
Vidal, L. [5 ,6 ]
Pautier, P. [7 ,8 ]
Ledermann, J. A. [9 ,10 ]
Penson, R. T. [11 ]
Oza, A. M. [12 ]
Korach, J. [13 ,14 ]
Huzarski, T. [15 ]
Pignata, S. [16 ,17 ]
Colombo, N. [18 ,19 ,20 ]
Park-Simon, T-W. [21 ,22 ]
Tamura, K. [23 ]
Sonke, G. S. [24 ,25 ]
Freimund, A. [26 ]
Lee, C. K. [27 ]
Pujade-Lauraine, E. [28 ]
机构：
[1] GINECO, Ctr Rene Gauducheau, St Herblain, France
[2] Inst Cancerol Ouest, St Herblain, France
[3] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] GEICO, Med Oncol, Barcelona, Spain
[6] H Clin Barcelona, Barcelona, Spain
[7] GINECO, Med Oncol, Villejuif, France
[8] Gustave Roussy Canc Ctr, Villejuif, France
[9] NCRI, Dept Oncol, London, England
[10] UCL, London, England
[11] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[12] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[13] ISGO, Dept Gynecol Oncol, Tel Aviv, Israel
[14] Chaim Sheba Med Ctr, Tel Aviv, Israel
[15] Pomeranian Med Univ, Int Hereditary Canc Ctr, Genet & Pathol, Szczecin, Poland
[16] MITO, Dept Urol & Gynecol, Naples, Italy
[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[18] MaNGO, Gynecol Oncol Dept, Milan, Italy
[19] European Inst Oncol, Milan, Italy
[20] Univ Milano Bicocca, Milan, Italy
[21] AGO, Gynecol Oncol, Hannover, Germany
[22] Hannover Med Sch, Hannover, Germany
[23] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[24] DGOG, Dept Med Oncol, Amsterdam, Netherlands
[25] Netherlands Canc Inst, Amsterdam, Netherlands
[26] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[27] St George Publ Hosp, Canc Care Ctr, Sydney, NSW, Australia
[28] ARCAGY GINECO, Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
813MO
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [31] Final overall survival results from SOLO3: Phase III trial assessing olaparib monotherapy versus non-platinum chemotherapy in heavily pretreated patients with germline BRCA1-and/or BRCA2-mutated platinum-sensitive relapsed ovarian cancer
    Penson, Richard
    Valencia, Ricardo Villalobos
    Colombo, Nicoletta
    Leath, Charles
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo
    Ryu, Sang-Young
    Milenkova, Tsveta
    Lowe, Elizabeth
    Lukashchuk, Natalia
    McNamara, John
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S19 - S20
  • [32] A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
    Mirza, Mansoor Raza
    Mortensen, Christiane Ehlers
    Christensen, Rene dePont
    Christoffersen, Louise
    Westergaard, Mia
    Boufercha, Louisa
    Birrer, Michael
    Avail-Lundqvist, Elisabeth
    Bjorge, Line
    Maenpaa, Johanna Unelma
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses
    Oza, A. M.
    Cibula, D.
    Oaknin Benzaquen, A.
    Poole, C. J.
    Mathijssen, R. H. J.
    Sonke, G. S.
    Mackay, H.
    Lowe, E. S.
    Read, J.
    Friedlander, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S712 - S713
  • [34] Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial
    Ledermann, Jonathan A.
    Lortholary, Alain
    Penson, Richard T.
    Gibbs, Emma
    Provencher, Diane M.
    Bruchim, Ilan
    Huzarski, Tomas
    Barretina-Ginesta, Maria Pilar
    Sabbatini, Roberto
    Mileshkin, Linda R.
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Matsumoto, Koji
    Sonke, Gabe S.
    Mikheeva, Olga N.
    Kim, Jae-Weon
    Girotto, Gustavo Colagiovanni
    Denys, Hannelore
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
    Lee, Jung-Min
    Trepel, Jane B.
    Choyke, Peter
    Cao, Liang
    Sissung, Tristan
    Houston, Nicole
    Yu, Minshu
    Figg, William D.
    Turkbey, Ismail Baris
    Steinberg, Seth M.
    Lee, Min-Jung
    Ivy, S. Percy
    Liu, Joyce F.
    Matulonis, Ursula A.
    Kohn, Elise C.
    FRONTIERS IN ONCOLOGY, 2015, 5
  • [36] Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report
    Skof, Erik
    Stegel, Vida
    Dragos, Vita Setrajcic
    Blatnik, Ana
    Gregoric, Brigita
    Skerl, Petra
    Klancar, Gasper
    Klasinc, Anja Zagozen
    Bombac, Alenka
    Kraje, Mateja
    Novakovic, Srdjan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 104 - 112
  • [37] Senaparib, a PARP inhibitor, in patients with BRCA1/2 mutated platinum sensitive recurrent ovarian cancer: subgroup analysis from Sabrina study
    Wu, Xiaohua
    Liu, Jihong
    Wang, Li
    Lin, Zhongqiu
    Wang, Jing
    Wang, Chunyan
    Kong, Beihua
    Liang, Zhiqing
    Cheng, Ying
    Wen, Hongwu
    Lou, Ge
    Huang, Yi
    Wang, Ke
    An, Ruifang
    Zhu, Xianqing
    Zhou, Huaijun
    Yue, Ying
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A73 - A74
  • [38] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
    Cecere, Sabrina Chiara
    Giannone, Gaia
    Salutari, Vanda
    Arenare, Laura
    Lorusso, Domenica
    Ronzino, Graziana
    Lauria, Rossella
    Cormio, Gennaro
    Carella, Claudia
    Scollo, Paolo
    Ghizzoni, Viola
    Raspagliesi, Francesco
    Di Napoli, Marilena
    Mazzoni, Enrica
    Marchetti, Claudia
    Bergamini, Alice
    Orditura, Michele
    Valabrega, Giorgio
    Scambia, Giovanni
    Maltese, Giuseppa
    De Matteis, Elisabetta
    Cardalesi, Cinzia
    Loizzi, Vera
    Boccia, Serena
    Naglieri, Emanuele
    Scandurra, Giuseppa
    Pignata, Sandro
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 38 - 44
  • [39] SURVIVAL OF PARP INHIBITOR (PARPI) NAIVE OVARIAN CANCER PATIENTS WITH A BRCA-MUTATION RECEIVING MAINTENANCE OLAPARIB AFTER CHEMOTHERAPY FOR FIRST RECURRENCE. AN EXPLORATORY ANALYSIS OF THE SOLO2/ENGOT-OV21 TRIAL
    Ledermann, Jonathan A.
    Ray-Coquard, Isabelle
    Penson, Richard
    Lee, Chee
    Oza, Amit
    Korach, Jacob
    Lainez, Nuria
    Scambia, Giovanni
    Gebski, Val
    Colombo, Nicoletta
    Welz, Julia
    Fujiwara, Keiichi
    Lowe, Elizabeth S.
    Pujade-Lauraine, Eric
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A243 - A243
  • [40] Cost-Effectiveness of BRCA1 and BRCA2 Mutation Testing to Target PARP Inhibitor Use in Platinum-Sensitive Recurrent Ovarian Cancer
    Secord, Angeles Alvarez
    Barnett, Jason Cory
    Ledermann, Jonathan A.
    Peterson, Bercedis L.
    Myers, Evan R.
    Havrilesky, Laura J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 846 - 852
12345